aidsoversixty

a reader's journal & virtual public artspace for poz platinum points of view, lgbt political & cultural activism & other metaphoric narratives of the struggle for social justice

Sacramento Bee: How to make big buck$$ from my sickness & sorrow: Specialty Pharmaceutical Industry – 2011 Yearbook

Specialty Pharmaceutical Industry – 2011 Yearbook
from the Sacramento Bee, August 31, 2011

NEW YORK, Aug. 30, 2011 — /PRNewswire/ –Reportlinker.com announces that a new market research report is available in its catalogue:

Specialty Pharmaceutical Industry – 2011 Yearbook

Summary

GBI Research’s “Specialty Pharmaceutical Industry – 2011 Yearbook” essentially provides insights on specialty pharmaceutical sales and price forecasts until 2017. The report provides in-depth therapeutics analysis of eight niche indications, namely: Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), age related macular degenerative disorders, attention deficit hyperactivity disorder (ADHD), Alzheimer’s disease,colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma, including their annual cost of therapy (ACT) and revenue. In addition, the geographical distribution of these disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the specialty pharmaceutical Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. Furthermore, it also covers the market forecasts and treatment usage patterns of these eight therapeutic indications up to 2017. Finally, the key trend analysis on Mergers and Acquisitions (M&A), licensing agreements and co-development deals involving specialty pharmaceuticals is also presented.

Scope

The report covers –

  • Annualized market data for the specialty pharmaceutical market from 2001 to 2009, with forecasts to 2017.
  • Market analysis for the eight major indications in the global specialty pharmaceutical market which includes HIV/AIDS, age related macular degenerative disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer’s disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma.
  • Data and analysis on the specialty pharmaceutical market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Key M&A activities and licensing agreements that took place from 2004 to 2010 in the specialty pharmaceutical market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to –

  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Table of Contents

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 9

2 Specialty Pharmaceutical Market- 2011 Yearbook: Introduction 12

2.1 Scope 12

2.2 GBI Research Report Guidance 12

3 Specialty Pharmaceutical Market- 2011 Yearbook: HIV Therapeutics Market 13

3.1 Disease Overview 13

3.2 Market Overview 14

3.3 Global HIV Therapeutics Market: Market Characterization 14

3.3.1 Market Forecasts 14

3.3.2 Annual Cost of Therapy 16

3.3.3 Usage Patterns 18

3.3.4 Geographical Distribution 24

3.4 HIV Therapeutics Market: Drivers and Restraints 26

3.4.1 Market Drivers 26

3.4.2 Market Restraints 29

4 Specialty Pharmaceutical Market- 2011 Year Book: Age Related Macular Degenerative Disorder 31

4.1 Disease Overview 31

4.2 Market Overview 31

4.3 Age Related Macular Degenerative Disorder: Market Characterization 32

4.3.1 Market Forecasts 32

4.3.2 Geographical Distribution 33

4.3.3 Annual Cost of Therapy 34

4.3.4 Usage Patterns 35

4.4 Age Related Macular Degenerative Disorder: Drivers and Restraints 39

4.4.1 Market Drivers 39

4.4.2 Market Restraints 40

5 Specialty Pharmaceutical Market- 2011 Yearbook: Attention Deficit Hyperactive Disorder (ADHD) 41

5.1 Introduction 41

5.2 Attention Deficit Hyperactive Disorder: Market Characterization 41

5.2.1 Market Forecasts 41

5.2.2 Geographical Distribution 43

5.2.3 Annual Cost of Therapy 44

5.2.4 Usage Patterns 45

5.3 Attention Deficit Hyperactive Disorder Market: Drivers and Restraints 50

5.3.1 Market Drivers 50

5.3.2 Market Restraints 50

6 Specialty Pharmaceutical Market- 2011 Yearbook: Alzheimer’s Disease 51

6.1 Introduction 51

6.2 Alzheimer’s disease: Market Characterization 51

6.2.1 Market Forecasts 51

6.2.2 Geographical Distribution 53

6.2.3 Annual Cost of Therapy 54

6.2.4 Usage Patterns 55

6.3 Alzheimer’s Disease Market: Drivers and Restraints 60

6.4 Market Drivers 60

6.5 Market Restraints 60

7 Specialty Pharmaceutical Market- 2011 Yearbook: Colorectal Cancer 61

7.1 Introduction 61

7.2 Colorectal Cancer: Market Characterization 61

7.2.1 Market Forecasts 61

7.2.2 Geographical Distribution 63

7.2.3 Annual Cost of Therapy 64

7.2.4 Usage Patterns 65

7.3 Colorectal Cancer Market: Drivers and Restraints 70

7.3.1 Market Drivers 70

7.3.2 Market Restraints 70

8 Specialty Pharmaceutical Market- 2011 Yearbook: Rheumatoid Arthritis 71

8.1 Introduction 71

8.2 Rheumatoid Arthritis: Market Characterization 71

8.2.1 Market Forecasts 71

8.2.2 Annual Cost of Therapy 73

8.2.3 Treatment Usage Patterns 74

8.2.4 Geographical Distribution 79

8.3 Rheumatoid Arthritis Market: Drivers and Restraints 80

8.3.1 Market Drivers 80

8.3.2 Market Restraints 80

9 Specialty Pharmaceutical Market- 2011 Yearbook: Epilepsy 81

9.1 Introduction 81

9.2 Epilepsy: Market Characterization 81

9.2.1 Market Forecasts 81

9.2.2 Geographical Distribution 83

9.2.3 Annual Cost of Therapy 84

9.2.4 Usage Patterns 85

9.3 Epilepsy Market: Drivers and Restraints 90

9.3.1 Market Drivers 90

9.3.2 Market Restraints 90

10 Specialty Pharmaceutical Market- 2011 Yearbook: Glaucoma 91

10.1 Introduction 91

10.2 Glaucoma: Market Characterization 91

10.2.1 Market Forecasts 91

10.2.2 Geographical Distribution 93

10.2.3 Annual Cost of Therapy 94

10.2.4 Usage Patterns 95

10.3 Glaucoma Market: Drivers and Restraints 100

10.3.1 Drivers of the Glaucoma Market 100

10.3.2 Barriers for the Glaucoma Market 100

11 Specialty Pharmaceutical Market- 2011Yearbook: Pipeline Analysis 102

11.1 Specialty Pharmaceutical Pipeline: HIV market 105

11.2 Molecule Profile for Promising Drugs under Clinical Development: HIV 106

11.2.1 Rilpivirine hydrochloride (TMC278) 106

11.2.2 Elvitegravir 107

11.2.3 Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad) 108

11.2.4 Racivir 109

11.2.5 Apricitabine (ATC) 110

11.2.6 Tesamorelin 111

11.3 Specialty Pharmaceutical Pipeline: Age Related Macular Degeneration 112

11.4 Molecule Profile for Promising Drugs under Clinical Development: Age Related Macular Degeneration 113

11.4.1 VEGF Trap-Eye 113

11.5 Specialty Pharmaceutical Pipeline: Attention Deficit Hyperactive Disorder 114

11.6 Molecule Profile for Promising Drugs under Clinical Development: Attention Deficit Hyperactive Disorder 115

11.6.1 ABT-894 (Sofinicline) 115

11.6.2 Eltoprazine 115

11.6.3 AZD3480 (TC-1734) (Isopronicline) 116

11.7 Specialty Pharmaceutical Pipeline: Alzheimer’s Disease 117

11.8 Molecular Profile for the Promising Drugs under Clinical Development: Alzheimer’s Disease 118

11.8.1 Bapineuzumab 118

11.8.2 Gammagard 119

11.8.3 Dimebon 120

11.8.4 Rember (Trx0014) (methylthionium chloride) 120

11.9 Specialty Pharmaceutical Pipeline: Colorectal Cancer 122

11.10 Molecule Profile for Promising Drugs under Clinical Development: Colorectal Cancer 123

11.10.1 Aflibercept 123

11.10.2 Brivanib 124

11.10.3 OncoVAX 125

11.10.4 TroVax 127

11.10.5 KRX-0401 (Perifosine) 128

11.11 Specialty Pharmaceutical Pipeline: Rheumatoid Arthritis 129

11.12 Profiles for Promising Drugs under Clinical Development: Rheumatoid Arthritis 130

11.12.1 T-614 (iguratimod) 130

11.12.2 CP-690550 130

11.12.3 Arzerra (HuMax-CD20 /Ofatumumab) 131

11.12.4 VX-509 132

11.13 Specialty Pharmaceutical Pipeline: Epilepsy 133

11.14 Molecule Profile for Promising Drugs under Clinical Development: Epilepsy 134

11.14.1 Stedesa (Eslicarbazepine Acetate) 134

11.14.2 Comfyde (Carisbamate) 135

11.14.3 Retigabine 136

11.14.4 Brivaracetam 137

11.14.5 Ganaxolone 137

11.14.6 E2007 (Perampanel) 138

11.15 Specialty Pharmaceutical Pipeline: Glaucoma 139

11.16 Molecule Profile for Promising Drugs under Clinical Development: Glaucoma 140

11.16.1 Tafluprost (Saflutan) 140

11.16.2 NCX-116 (Formerly PF-03187207) 141

12 Specialty Pharmaceutical Market- 2011 Yearbook: Strategic Consolidations 142

12.1 Mergers and Acquisitions 142

12.1.1 Pfizer 144

12.1.2 F. Hoffmann-La Roche 146

12.1.3 GlaxoSmithKline 146

12.2 Licensing Deals 148

12.2.1 Pfizer 149

12.2.2 F. Hoffmann-La Roche 151

12.2.3 GlaxoSmithKline 153

12.3 Co-Development Deals 155

12.3.1 Pfizer 156

12.3.2 F. Hoffmann-La Roche 158

12.3.3 GlaxoSmithKline 160

13 Specialty Pharmaceutical Market- 2011 Yearbook: Appendix 162

13.1 Market Definitions 162

13.2 Abbreviations 162

13.3 Research Methodology 163

13.3.1 Coverage 163

13.3.2 Secondary Research 164

13.3.3 Primary Research 164

13.3.4 Forecasts 164

13.3.5 Expert Panel Validation 167

13.4 Contact Us 167

13.5 Disclaimer 167

13.6 Sources 167

Read more: http://www.sacbee.com/2011/08/30/3871232/specialty-pharmaceutical-industry.html#ixzz1WdTSADvN

Advertisements

Filed under: Uncategorized

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

archives

---pages

blogroll

dictionaries & glossaries

elder links

fourth estate --- journalism, politics, storytelling & watchdoggery

HIV/AIDS specific

lgbt specific

medical cannabis

rhetoric, grammar & logic

wordpress

%d bloggers like this: